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Coronavirus disease 2019 (COVID-19) has 
fundamentally changed everything since De-
cember 2019 when World Health Organization 
(WHO) confirmed this virus for the first time. 
A novel coronavirus, SARS-CoV-2, spread ex-
tremely fast around the globe and WHO claimed 
a global pandemic in March 2020. 
One of the most important questions that 
was raised at the beginning of the pandemic 
has been risk factors that are associated with 
SARS-CoV-2 infection, worse clinical manifes-
tation of COVID-19 and adverse outcome. The 
first results indicated that advanced age, male 
sex, previous cardiovascular, and respiratory 
diseases were risk factors for infection and 
worse clinical outcomes (treatment in intensive 
care units, intubation, and in-hospital mortality) 
[1]. However, these studies were usually per-
formed in a single center, included a limited 
number of patients of only one race, provided 
a relatively short follow-up with scarce infor-
mation about confounding factors that might 
interfere the final results [1]. Due to the lack of 
data about potential confounding factors and 
misinterpretation of obtained results, angio-
tensin-converting enzyme inhibitors (ACEIs) 
and angiotensin II receptor blockers (ARBs) 
were declared as potentially dangerous in 
COVID-19 patients [2], which raised many ques-
tions. Fortunately, extensive sets data showed 
that ACEIs and ARBs were not associated with 
higher risk of infection, intubation or mortality 
in COVID-19 patients [3]. 
In this issue of Kardiol Pol, Terlecki et al. [4] 
reported data about the relationship between 
cardiovascular (CV) diseases, CV therapy, and 
in-hospital mortality in the large cohort of 
COVID-19 patients from a single-center registry 
in Poland. The authors confirmed existing ev-
idence that advanced age, male sex, diabetes 
mellitus, and pre-existing heart failure were 
the major predictors of adverse outcomes 
in these patients. The most innovative part 
of this investigation refers to the protective 
effect of CV medications, including ACEI/ARB, 
beta-blockers, statins, and antiplatelet agents, 
in COVID-19 patients [4].
The most prevalent CV diseases in this study 
were arterial hypertension, hyperlipidemia, di-
abetes mellitus, coronary artery disease, heart 
failure, atrial fibrillation, and stroke [4]. Age over 
65 years, male sex, pre-existing diabetes melli-
tus, and heart failure were independent predic-
tors of in-hospital mortality, whereas treatment 
with ACEIs/ARBs, beta-blockers (BBs), statins, 
or antiplatelet therapy was related with lower 
in-hospital mortality [4]. Stroke also showed 
a borderline significance as an independent 
predictor of in-hospital mortality (P = 0.07).
The effect of ACEI/ARB on outcome in 
COVID-19 patients has not been completely 
understood because results still vary in dif-
ferent studies depending of which outcome 
has been investigated and which parameters 
were used for adjustment in statistical models 
[5]. In a large cohort of 824 650 patients with 
hypertension from a US integrated healthcare 
system it was found that ACEI/ARB use did not 
increase the risk of COVID-19  [5]. Interestingly, 
ACEI use was associated with decreased risk of 
COVID-19  among hypertensive patients older 
than 85 years. A recently published meta-anal-
ysis revealed that the use of ACEI/ARB was 
independently associated with the reduction 
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of severe adverse events and mortality in all patients, as 
well as in a subgroup of hypertensive patients [6]. Ren et al. 
[7] included 2,100,587 participants in a meta-analysis and 
revealed no association between prior usage of antihyper-
tensive medications including ACEIs/ARBs, calcium channel 
blockers (CCBs), BBs, or diuretics and the risk and severity of 
COVID-19. Furthermore, the severity and mortality were sig-
nificantly lower in hypertensive patients with prior usage of 
ACEIs/ARBs [7]. The beneficial effect of statins on mortality 
in COVID-19 has been also recently reported [8]. However, 
there are also large studies that showed no evidence that 
antihypertensive therapy was associated with increased 
risk of COVID-19  or mortality [9]. ACEI/ARBs, CCBs and diu-
retics were associated with lower risk of COVID-19, whereas 
only BBs were associated with higher risk of COVID-19  [9]. 
Another investigation showed that BBs were independently 
associated with better outcomes and less severe course of 
disease, whereas CCBs correlated with poor outcomes (ICU 
admission and mortality) [10]. ACEI/ARBs and diuretics were 
not associated with any outcomes [10].
The effect of antithrombotic therapy, both antiplatelet 
and anticoagulant treatment, on outcomes in COVID-19 has 
not been established yet. Russo et al. [11] have recently 
reported that such a type of therapy was not associated 
with better outcome in patients with severe COVID-19 with 
acute respiratory syndrome at presentation. A meta-anal-
ysis that included 5970 COVID-19 patients confirmed that 
antiplatelet therapy did not decrease mortality in these 
patients [12]. On the other hand, the study that included 
almost 2000 COVID-19 patients reported positive effect of 
aspirin on in-hospital mortality [13].
The major limitation of available studies is the lack 
of information about the control of the primary disease 
(hypertension, heart failure, coronary artery disease, atrial 
fibrillation) and its control before and during COVID-19. The 
recent study demonstrated that patients with stage 1 un-
controlled blood pressure (140/90–159/99 mm Hg) had 
lower risk of COVID-19 death compared with those with 
well-controlled blood pressure, who were older, had more 
comorbidities, and had been diagnosed with hypertension 
for a longer period of time [14]. However, in the study in 
which patients are of similar age, prevalence of comorbid-
ities and duration of hypertension, one would expect that 
control of main comorbidities in COVID-19 patients, such 
as hypertension, heart failure, diabetes, atrial fibrillation 
or coronary artery disease, have an essential role in the 
prediction of outcome in COVID-19 patients. The study by 
Terlecki et al. [4] did not include other medications, such 
as diuretics, antidiabetics, and anticoagulants in the final 
multivariable analysis. Even though data about body mass 
index (BMI) and creatinine level were provided, the authors 
did not consider the effect of obesity or renal dysfunction 
on the outcomes in this population. The same is true with 
the potential effect of pulmonary diseases (asthma and 
chronic obstructive pulmonary disease [COPD]) that was 
not examined in the statistical model. Data about specific 
or unspecific therapy used for treatment of COVID-19, aside 
from oxygen therapy, were not provided, and it might be 
essential in prediction of adverse outcomes. 
The diversity of published results about the impact of 
CV diseases and therapy on outcome in COVID-19 patients 
reveals the lack of understanding of mechanisms that 
would potentially explain the relationship (positive or 
negative) between CV drugs and COVID-19. Furthermore, 
the detailed analysis of all potential risk factors on severity 
of COVID-19 and its outcome, with longer follow-up would 
be very much appreciated.
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